Pfizer extends AI collaboration with Saama

Saama, a company specialising in AI-powered solutions for expediting clinical development and commercialisation, has announced an extended partnership with Pfizer, a global leader in biopharmaceuticals, aimed at accelerating the pace of clinical research.

This renewed agreement builds upon a strategic partnership initiated in 2020, where Saama and Pfizer collaborated to automate Pfizer’s data review processes using artificial intelligence (AI), resulting in the development of Smart Data Quality (SDQ). SDQ significantly reduced the time needed for database lock. With this updated agreement, Pfizer plans to expand the implementation of SDQ to streamline and expedite data review processes across its extensive portfolio of global studies.

In addition to SDQ, the enhanced agreement expands the scope of collaboration to assist Pfizer in expediting regulatory submissions across its portfolio through Saama’s advanced Biometrics Research and Analysis Information Network. This cutting-edge solution streamlines statistical programming and biostatistics workflows, digitises study specifications, and generates submission-ready tables, listings, and figures (TLF) artifacts. This initiative sets the stage for ongoing automation and innovation to further accelerate future trial submissions.

 Lisa Moneymaker, Chief Technology Officer and Chief Product Officer, Saama said “Our initial collaboration with Pfizer for its COVID-19 vaccine demonstrated the unprecedented power of our AI-enabled technology platform to improve and accelerate the clinical trial process, and ultimately, its ability to help bring treatments to patients faster,”

Demetris Zambas, Vice President and Global Head Data Monitoring and Management, Pfizer also commented saying “We look forward to expanding our strategic partnership with Saama across our global portfolio, leveraging their cutting-edge, AI-based technologies to reduce the time and effort required for data review and reconciliation, and to improve the quality and consistency of data across routine and complex clinical studies alike.”

Click here to read the original news story.